Sue S, et al. - This multicenter, prospective, randomized trial was performed to validate the eradication rate of vonoprazan-based first-line triple therapy (combined with clarithromycin and amoxicillin) (V-AC) using clarithromycin (CAM)-susceptible testing. In the CAM-susceptible H. pylori-infected patients, the eradication rate of V-AC treatment was <90%, as was that by proton-pump inhibitor-AC, thus V-AC was not ideal regimen in CAM-susceptible H. pylori. However, in the CAM-resistant infections, the 82.9% eradication rate of V-AC could indicate the potential of V-AC with modified dose, dosing interval, and treatment duration.